Rosetta Genomics Company Profile (NASDAQ:ROSG)

Analyst Ratings

Consensus Ratings for Rosetta Genomics (NASDAQ:ROSG) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.33 (211.53% upside)

Analysts' Ratings History for Rosetta Genomics (NASDAQ:ROSG)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016AegisReiterated RatingBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Barrington ResearchLower Price TargetOutperform$5.00 -> $3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Rosetta Genomics (NASDAQ:ROSG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/25/2016        
5/19/2016Q116($0.16)($0.18)$3.36 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q415($0.33)($0.14)$3.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/1/2015Q315$0.27$2.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rosetta Genomics (NASDAQ:ROSG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.18)($0.18)($0.18)
Q2 20161($0.17)($0.17)($0.17)
Q3 20161($0.16)($0.16)($0.16)
Q4 20161($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rosetta Genomics (NASDAQ:ROSG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Rosetta Genomics (NASDAQ:ROSG)
DateHeadline
07/29/16 06:20 PMExpected For Rosetta Genomics Ltd. (NASDAQ:ROSG) Sales Of $74.285 - Investor Newswire
07/24/16 10:15 AMRosetta Genomics Ltd. (NASDAQ:ROSG) Expected To Post Sales Of $74.285 - Investor Newswire
07/18/16 11:44 AMRosetta Genomics Limited Ord (NASDAQ:ROSG) Shorted Shares Decreased By 2.52% - Consumer Eagle
07/13/16 06:35 PMRosetta Genomics gets US patent for microRNA-based ovarian cancer treatment
07/13/16 09:06 AMRosetta Genomics Limited Ord (NASDAQ:ROSG) Shorts Decreased by 2.52% After Short Covering - Consumer Eagle
07/12/16 10:34 AMRosetta Genomics (ROSG) Receives USPTO Notice of Allowance on '548 Patent App
07/11/16 12:23 PMRosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment - [at noodls] - ba43178f-184c-42a1-a9cc-cacd2d837b3f.pdf News Release Receives Two Notices of Allowance in Israel PHILADELPHIA and REHOVOT, Israel (July 11, 2016) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer ...
07/11/16 11:37 AMRosetta Genomics Gets Patent Allowance For microRNA-based Ovarian Cancer Treatment - Rosetta Genomics Ltd. (NASDAQ: ROSG) revealed that the Patent and Trademark Office in the United States has issued a notice of allowance for its patent, entitled "Compositions and methods for treatment of Ovarian Cancer." According to the company, it covered a method of treatment for ovarian cancer by administering an inhibitor of miR-27a. Aside from that, Rosetta said the Israel Patent Office has also allowed its Application entitled "Compositions and Methods for Modulating Cell Proliferation and Cell Death," to claim use of miR-34a or its ...Full story available on Benzinga.com
07/11/16 10:49 AMRosetta Genomics (ROSG) Receives USPTO Notice of Allowance on '548 Patent App - StreetInsider.com
07/10/16 05:26 PMBrokers Issue Average Price Target Of 5.12 On Rosetta Genomics Ltd. (ROSG) - Fiscal Standard
07/10/16 05:26 PMRosetta Genomics Ltd. (ROSG) Broker Price Targets For The Coming Week - Fiscal Standard
07/07/16 06:15 PMRosetta Genomics Limited Ord (NASDAQ:ROSG) Sellers Covered 2.52% of Their Shorts - Engelwood Daily
07/07/16 06:15 PMRosetta Genomics Ltd. (ROSG) Updated Price Targets - FTSE News
07/06/16 06:31 PMRosetta Genomics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
07/06/16 07:00 AMRosetta Genomics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Cantor Fitzgerald’s 2nd Annual Healthcare Conference taking place July 12-13, 2016 in New York City.
07/05/16 10:37 AMBroker Outlook For The Week Ahead Rosetta Genomics Ltd. (ROSG) - Fiscal Standard
07/02/16 08:51 AMSales of $74.285 expected for Rosetta Genomics Ltd. (NASDAQ:ROSG) - Investor Newswire
07/01/16 06:11 PMNew Broker Ratings For Rosetta Genomics Ltd. (ROSG) - FTSE News
06/24/16 06:17 PMRosetta Genomics Ltd. (NASDAQ:ROSG) Yearly Sales Target At $74.285 - Investor Newswire
06/24/16 06:17 PMRosetta Genomics Ltd. (USA) (NASDAQ:ROSG) Completes 50-State Sweep For Its FISH Tests - Scibility Media
06/23/16 08:49 AMRosetta Genomics (ROSG) Wins Conditional New York State Approval for HEME FISH-based Assays
06/23/16 08:49 AMRosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
06/23/16 08:49 AMBRIEF-Rosetta Genomics Ltd announces agreement with Preferred Provider Organization
06/23/16 08:49 AMRosetta Genomics USA : Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
06/22/16 12:01 PMRosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 -
06/22/16 10:54 AM8 Biggest Mid-Day Gainers For Tuesday - Benzinga
06/22/16 10:54 AMRosetta Genomics (ROSG) Wins Conditional New York State Approval for HEME FISH-based Assays - StreetInsider.com
06/22/16 10:54 AMLast Analysts Rating Review: Rosetta Genomics Ltd. (NASDAQ:ROSG) , Medtronic plc (NYSE:MDT) - Street Updates
06/21/16 10:29 AMRosetta Genomics Receives Approval from New York State for HEME FISH-based Assays
06/21/16 10:19 AMHere’s Why These Five Stocks Are Gaining Ground on Tuesday -
06/19/16 09:57 AMRosetta Genomics Ltd. (NASDAQ:ROSG) Yearly Sales Projections At $74.285 - Investor Newswire
06/17/16 08:54 AMEnvision Healthcare Holdings, Inc. (NYSE:EVHC) plummeted -6.18%: Rosetta Genomics, Ltd. (NASDAQ:ROSG ... - KC Register
06/11/16 06:21 PMCan Rosetta Genomics Ltd. (NASDAQ:ROSG) Keep Up with Analyst Expectations? - Investor Newswire
06/03/16 09:07 AMBroker Watchlist: Rosetta Genomics Ltd. (ROSG) - Share Trading News
05/26/16 11:59 PMRevenue Update on Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG) - Trade Calls - Revenue Update on Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG)Trade CallsRosetta Genomics Ltd. (USA)(NASDAQ:ROSG) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 19, 2016. Earnings per share were $-0.18. Rosetta Genomics Ltd. (USA) (ROSG) made into the ...Rosetta Genomics (ROSG) Announces Publication of Positive Thyroid Nodule Classification Assay DataStreetInsider.comRosetta Genomics Reports Positive Data on Novel Thyroid Nodule Classification Test; Shares Flat Pre Bell (NASDAQ ...Sonoran Weekly Reviewall 3 news articles »
05/26/16 07:06 AMRosetta Genomics (ROSG) Announces Publication of Positive Thyroid Nodule Classification Assay Data - StreetInsider.com - Rosetta Genomics (ROSG) Announces Publication of Positive Thyroid Nodule Classification Assay DataStreetInsider.comRosetta Genomics Ltd. (Nasdaq: ROSG) announced that data from the analytical validation of the Company's novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, ...and more »
05/26/16 06:00 AMRosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company’s novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, Cancer Cytopathology.
05/25/16 10:19 AMLatest Analyst Ratings For Rosetta Genomics Ltd. (ROSG) - Share Trading News - Latest Analyst Ratings For Rosetta Genomics Ltd. (ROSG)Share Trading News03/28/2016 – Rosetta Genomics Ltd. had its “outperform” rating reiterated by analysts at Barrington Research. They now have a USD 3.5 price target on the stock. 03/24/2016 – Aegis Capital began new coverage on Rosetta Genomics Ltd. giving the company ...
05/23/16 11:53 AMRosetta Genomics (ROSG) Announces New York State Approval for Four PCR-Based Assays - StreetInsider.com - Rosetta Genomics (ROSG) Announces New York State Approval for Four PCR-Based AssaysStreetInsider.comRosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health (NYSDOH) for the ...and more »
05/23/16 07:05 AM8:05 am Rosetta Genomics receives conditional approval from the NY State Department of Health for four allele-specific PCR (CAST PCR)-based assays -
05/23/16 07:00 AMRosetta Genomics Receives Approval from New York State for Four PCR-Based Assays - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health for the Company’s allele-specific PCR -based assays to test for BRAF, EGFR, KRAS and NRAS mutations in lung, colon and melanoma cancers.
05/19/16 11:53 PMRosetta Genomics USA : Reports 2016 First Quarter Financial Results - 02:05p ROSETTA GENOMICS USA: Reports 2016 First Quarter Financial Results 05/16 ROSETTA GENOMICS USA: to Host 2016 First Quarter Financial Results and Business.. 03/23 ROSETTA GENOMICS USA: Reports 2015 Full Year Financial Results 03/17 ROSETTA GENOMICS ...
05/19/16 02:41 PMEdited Transcript of ROSG earnings conference call or presentation 19-May-16 2:00pm GMT -
05/19/16 10:02 AMRosetta Genomics Reports 2016 First Quarter Results - [at noodls] - c351f672-b264-4de6-97c6-3ed334884085.pdf News Release Rosetta Genomics Reports 2016 First Quarter Financial Results Record Quarterly Clinical Testing Revenues of $2.6 million Conference call begins today ...
05/19/16 07:00 AMRosetta Genomics Reports 2016 First Quarter Financial Results - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.
05/19/16 06:07 AMQ1 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open -
05/18/16 06:42 PMRosetta Genomics Ltd. (NASDAQ:ROSG) To Release Earnings On Thursday - Share Trading News - Rosetta Genomics Ltd. (NASDAQ:ROSG) To Release Earnings On ThursdayShare Trading NewsAt the moment 4 analysts are watching Rosetta Genomics Ltd. (NASDAQ:ROSG), 0 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”. Looking forward, for the quarter ending Jun-16, 2 analysts have a mean sales target of 3.81 million.
05/16/16 01:22 PMRosetta Genomics to Host 2016 First Quarter Financial and Business Update Conference Call on May 19, 2016 - [at noodls] - f22d8f3d-4f8b-45a6-97d3-85bb5e53a08f.pdf News Release Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016 PHILADELPHIA, PA. and REHOVOT, Israel ...
05/16/16 07:00 AMRosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016 - [Business Wire] - Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S.
05/14/16 12:08 AMRosetta Genomics Ltd. (NASDAQ:ROSG) Latest Impact Score At 0 - Stocks Daily - Rosetta Genomics Ltd. (NASDAQ:ROSG) Latest Impact Score At 0Stocks DailyRosetta Genomics Ltd. (NASDAQ:ROSG) has a -0.217 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published on ...and more »

Social

About Rosetta Genomics

Rosetta Genomics logoRosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ROSG
  • CUSIP:
Key Metrics:
  • Previous Close: $1.07
  • 50 Day Moving Average: $1.12
  • 200 Day Moving Average: $1.12
  • P/E Ratio: N/A
  • P/E Growth: -0.11
  • Market Cap: $22.31M
  • Beta: -3.48
  • Current Year EPS Consensus Estimate: $-0.63 EPS
  • Next Year EPS Consensus Estimate: $-0.55 EPS
Additional Links:
Rosetta Genomics (NASDAQ:ROSG) Chart for Saturday, July, 30, 2016